Plain-English translation of NCT06058234 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is tracking how anti-amyloid-beta monoclonal antibodies work for people with early memory loss or mild Alzheimer's disease. Researchers will enroll about 8,680 Medicare patients who are receiving this medication and monitor how they respond over time. The study collects information about patients' thinking and daily functioning to help Medicare understand whether this treatment is helpful.
Early forms of memory loss and Alzheimer's disease affect many older adults, and doctors need real-world evidence to understand how well new treatments work in everyday practice settings. This study will help Medicare and healthcare providers make informed decisions about when and how to use this medication.
You likely qualify if…
You likely don't qualify if…
If you qualify, your doctor will evaluate your thinking and daily functioning at the start and then every 6 months for up to 2 years (5 visits total). Your doctor will report this information to a registry and also track whether you experience any side effects related to the medication, particularly brain imaging abnormalities. The main commitment is allowing your healthcare provider to share your medical progress data as you receive the treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Enrollment target
~8,680 participants
Started
July 2023
Primary completion
June 2028
Last updated on clinicaltrials.gov in September 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
CMS CAG
Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.